Indium (111in) Chloride Curium Netherlands (Indium (111in))

After intravenous injection, Indium-111 chloride either binds to plasma proteins or is incorporated into labeled leukocytes. The isotope emits gamma photons that are detected by a gamma camera. Accumulation occurs in areas with increased vascular permeability, active bone marrow, or malignant tissue, allowing high‑resolution images of these regions.

The administered activity of Indium-111 chloride is determined by the prescribing physician based on the specific diagnostic indication, patient weight, and the imaging protocol of the nuclear medicine department. Dosing is individualized and should follow the relevant professional guidelines and local regulatory requirements.

Safety data for Indium-111 chloride in pregnant or lactating women are limited, and the product is classified as having an unknown risk. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and after careful consideration by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Indium-111 chloride offers a relatively long half‑life (≈2.8 days) and gamma emissions suitable for high‑resolution imaging, making it valuable for leukocyte labeling and bone‑marrow studies. Compared with technetium‑99m agents, it provides longer imaging windows but involves higher radiation exposure; selection depends on the clinical question and logistical considerations.

The product must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. During handling, use radiation safety measures, wear appropriate protective equipment, and follow local regulations for radioactive material.

Indium-111 chloride is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The injection is typically performed under aseptic conditions, and the patient is monitored for any immediate reactions during and after the procedure.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension requiring medical intervention, and rare radiation‑induced tissue injury, especially with repeated high‑dose exposures. Prompt recognition and management of these events are essential.

Indium-111 chloride should be avoided in patients with a known hypersensitivity to the product or its components, in individuals where the diagnostic benefit does not outweigh the radiation risk (e.g., certain pregnant women), and in patients with severe uncontrolled cardiac or hemodynamic instability.